Poster A003: Immunocompetent AML Model for Preclinical Efficacy Testing

Developing an AML Mouse Syngeneic Model for Combinatory Chemotherapy and Immunotherapy

Xin Tang, Lily Tong, Annie Xiaoyu An, Likun Zhang, Jie Cai, Qian Shi, Jean-Pierre Wery, and Davy Xuesong Ouyang

Acute myeloid leukemia (AML) treatment options stagnated for many years, until the approval of multiple targeted agents in 2017. The advance of immunotherapeutics, and the approval of immune checkpoint inhibitors, is also offering new treatment options in hematological malignancies.

However, we are lacking appropriate immunocompetent AML models to test immuno-oncology agents and their combination with new targeted agents and/or chemotherapies. To meet this need, Crown Bioscience set out to develop a series of syngeneic AML mouse models carrying NRAS mutations and/or a set of clinically relevant fusion proteins, such as AML1/ETO9a.

This poster details the establishment of an AML1/ETO9a model in immunocompetent mice via retroviral infection, including GFP positive cells which can be used to monitor leukemia progression.

Read this Poster to Discover:

• An AML model with clinically relevant mutations for preclinical efficacy assessment of combinatory chemotherapies, targeted therapies, and immunotherapies
• Model validation including immunoprofiling of PBMCs, showing high expression of PD-L1 and c-kit, and low expression levels for Gr-1, CD45, Mac-1, and sca-1
• That initial treatment data has shown efficacy for doxorubicin, cytarabine, sorafenib, anti-CTLA-4, and anti-PD-1 antibodies in this model

Download the Poster Now!